KALV

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Cambridge, Massachusetts. The company went public in April 2015 and focuses on discovering, developing, and commercializing small molecule protease inhibitors for rare diseases with significant unmet medical needs. KalVista specializes in targeting the kallikrein-kinin system, a biological pathway involved in inflammation and vascular permeability, with particular emphasis on developing treatments for hereditary angioedema and diabetic macular edema.